Bosh sahifaEXEL • NASDAQ
add
Exelixis Inc
43,03 $
Seans yopilganidan keyin:(0,070%)-0,030
43,00 $
Yopilgan:6-iyn, 20:00:00 (GMT-4) · USD · NASDAQ · Ogohlantirish
Yopilish kursi
42,37 $
Kunlik diapazon
42,35 $ - 43,06 $
Yillik diapazon
21,36 $ - 48,85 $
Bozor kapitalizatsiyasi
11,73 mlrd USD
Oʻrtacha hajm
3,38 mln
Narx/foyda
19,52
Dividend daromadliligi
-
Asosiy maydon
NASDAQ
Yangiliklarda
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
| (USD) | mar, 2025info | Y/Y qiyosi |
|---|---|---|
Daromad | 555,45 mln | 30,62% |
Joriy xarajat | 349,42 mln | 2,27% |
Sof foyda | 159,62 mln | 327,73% |
Sof foyda marjasi | 28,74 | 227,33% |
Har bir ulushga tushum | 0,62 | 264,71% |
EBITDA | 194,20 mln | 182,79% |
Amaldagi soliq stavkasi | 22,40% | — |
Balans
Jami aktivlari
Jami passivlari
| (USD) | mar, 2025info | Y/Y qiyosi |
|---|---|---|
Naqd pul va qisqa investitsiyalar | 1,03 mlrd | 7,07% |
Jami aktivlari | 2,84 mlrd | 1,19% |
Jami passivlari | 706,22 mln | 4,51% |
Umumiy kapital | 2,13 mlrd | — |
Tarqatilgan aksiyalar | 272,71 mln | — |
Narxi/balansdagi bahosi | 5,47 | — |
Aktivlardan daromad | 16,15% | — |
Kapitaldan daromad | 19,55% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
| (USD) | mar, 2025info | Y/Y qiyosi |
|---|---|---|
Sof foyda | 159,62 mln | 327,73% |
Operatsiyalardan naqd pul | 211,44 mln | 207,22% |
Sarmoyadan naqd pul | 49,76 mln | -55,49% |
Moliyadan naqd pul | -294,82 mln | -60,19% |
Naqd pulning sof oʻzgarishi | -33,62 mln | -879,38% |
Boʻsh pul | 139,07 mln | 214,88% |
Haqida
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration for medullary thyroid cancer with clinical activity in several other types of metastatic cancer. Wikipedia
Tashkil etilgan
15-noy, 1994
Sayt
Xodimlar soni
1 147
